Management of hypercholesterolemia. Approach to diet and drug therapy

The American Journal of Medicine

Volumn 87, Issue SUPPL. 4, 1989, Pages

  Stein, Evan A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; COMPACTIN; ETOFIBRATE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

CATARACT; DIET; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ADULT; DIET THERAPY;

ADULT; HUMAN; HYPERCHOLESTEROLEMIA;

EID: 0024972434     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(89)80595-9     Document Type: Article

References (27)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results I Reduction in incidence of coronary heart disease
2. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
3. Fifteen years mortality in coronary drug project patients: long-term benefit with niacin
4. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
5. Evaluation and Treatment of High Blood Cholesterol in Adults
6. Current status of blood cholesterol measurement in clinical laboratories in the United States: a report from the Laboratory Standardization Panel of the National Cholesterol Education Program
7. Low-dose colestipol plus probucol for hypercholesterolemia
8. Lipid lowering drugs: an overview of indications and optimum therapeutic use
9. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanics of action of niacin
10. Competitive inhibition of 3-hydroxy-3-methyl glutaryl co-enzyme A reductase by ML-236A and ML-236B. fungal metabolites having hypocholesterolemic activity
11. Lovastatin (mevinolin) in the treatment of heterozygous familial nypercholesterolemia a multicenter study
12. Therapeutic response to lovastatin (mevinolin) in non-familial nypercholesterolemia
13. Lovastatin Study Group III: a multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia
14. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia
15. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects
16. Efficacy and long-term adverse effect pattern of lovastatin
17. Myelosis and acute renal failure in heart transplant patients receiving lovastatin (letter)
18. HMG-CoA reductase inhibitors for hypercholesterolemia (letter)
19. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia
20. Lovastatin alone and in combination for treatment of primary hypercholesterolemia
21. Complementarity of colestipol. niacin. and lovastatin in treatment of severe familial hypercholesterolemia
22. A comparison of lovastatin and probucol for the treatment of primary hypercholesterolemia (abstr)
23. Probucol inhibits oxidative modification of low density lipoprotein
24. Fenofibrate: a third generation fibric acid derivative
25. New lipid lowering agents: efficacy and combination therapy
26. Treatment of severe familial hypercholesterolemia with lovastatin, resin, and niacin (abstr)
27. Triple drug therapy for heterozygous familial hypercholesterolemia